Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 18
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Citrome, Leslie McEvoy, Joseph P. and Saklad, Stephen R. 2016. A Guide to the Management of Clozapine-Related Tolerability and Safety Concerns. Clinical Schizophrenia & Related Psychoses, Issue. aop,

    Druais, Sylvain Doutriaux, Agathe Cognet, Magali Godet, Annabelle Lançon, Christophe Levy, Pierre Samalin, Ludovic and Guillon, Pascal 2016. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France. PharmacoEconomics, Vol. 34, Issue. 4, p. 363.

    Elkis, Helio and Buckley, Peter F. 2016. Treatment-Resistant Schizophrenia. Psychiatric Clinics of North America, Vol. 39, Issue. 2, p. 239.

    Jaeschke, Rafał R. Sowa-Kućma, Magdalena Pańczyszyn-Trzewik, Patrycja Misztak, Paulina Styczeń, Krzysztof and Datka, Wojciech 2016. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. Pharmacological Reports, Vol. 68, Issue. 4, p. 748.

    Wei Xin Chong, Joyce Hsien-Jie Tan, Earl Chong, Chia Eng Ng, Yiwei and Wijesinghe, Ruki 2016. Atypical antipsychotics: A review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects. Mental Health Clinician, Vol. 6, Issue. 4, p. 178.

    Garay, Ricardo P Samalin, Ludovic Hameg, Ahcène and Llorca, Pierre-Michel 2015. Investigational drugs for anxiety in patients with schizophrenia. Expert Opinion on Investigational Drugs, Vol. 24, Issue. 4, p. 507.

    Kato, Tadafumi 2015. Whole genome/exome sequencing in mood and psychotic disorders. Psychiatry and Clinical Neurosciences, Vol. 69, Issue. 2, p. 65.

    Kato, Yamato Umetsu, Ryogo Abe, Junko Ueda, Natsumi Nakayama, Yoko Kinosada, Yasutomi and Nakamura, Mitsuhiro 2015. Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports. Journal of Pharmaceutical Health Care and Sciences, Vol. 1, Issue. 1,

    Majer, Istvan M. Gaughran, Fiona Sapin, Christophe Beillat, Maud and Treur, Marteen 2015. Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. Journal of Market Access & Health Policy, Vol. 3,

    Saklad, Stephen R. Kreys, Tiffany-Jade and Phan, Stephanie 2015. Aripiprazole long-acting injectable (ABILIFY MAINTENA) for treatment of schizophrenia. Mental Health Clinician, Vol. 5, Issue. 4, p. 149.

    2015. Therapie Psychischer Erkrankungen.

    Ferron, Gwenael Martinez, Alejandra Gladieff, Laurence Mery, Eliane David, Isabelle Delannes, Martine Montastruc, Marion Balagué, Gisèle Picaud, Laetitia and Querleu, Denis 2014. Adherence to Guidelines in Gynecologic Cancer Surgery. International Journal of Gynecological Cancer, Vol. 24, Issue. 9, p. 1675.

    Morrissette, Debbi A. and Stahl, Stephen M. 2014. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectrums, Vol. 19, Issue. 05, p. 439.

    Shirley, Matt and Perry, Caroline M. 2014. Aripiprazole (ABILIFY MAINTENA®): A Review of Its Use as Maintenance Treatment for Adult Patients with Schizophrenia. Drugs, Vol. 74, Issue. 10, p. 1097.

    Stahl, Stephen M. 2014. Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits. CNS Spectrums, Vol. 19, Issue. 05, p. 357.

    2014. Therapie Psychischer Erkrankungen.

    Burghardt, Kyle J. Gardner, Kristen N. Johnson, Joshua W. and Ellingrod, Vicki L. 2013. Fatty Acid Desaturase Gene Polymorphisms and Metabolic Measures in Schizophrenia and Bipolar Patients Taking Antipsychotics. Cardiovascular Psychiatry and Neurology, Vol. 2013, p. 1.

    Citrome, Leslie 2013. A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach. CNS Drugs, Vol. 27, Issue. 11, p. 879.


“Meta-guidelines” for the management of patients with schizophrenia

  • Stephen M. Stahl (a1) (a2) (a3) (a4), Debbi A. Morrissette (a3), Leslie Citrome (a5), Stephen R. Saklad (a6) (a7) (a8), Michael A. Cummings (a4), Jonathan M. Meyer (a1) (a4), Jennifer A. O'Day (a4), Laura J. Dardashti (a4) and Katherine D. Warburton (a4)
  • DOI:
  • Published online: 16 April 2013

Guidelines for treating various conditions can be helpful in setting practice standards, but the presence of several sets of guidelines from different countries, experts, and settings, written at different times, can also create confusion. Here we provide a “guideline of guidelines” for the treatment of schizophrenia, or “meta-guidelines,” which not only reconcile the various existing standards but also update them to include the use of several newer agents, most of which were marketed following the publication of existing standards.

Corresponding author
*Address for correspondence: Stephen M. Stahl, MD, PhD, 1930 Palomar Point Way, Suite 103, Carlsbad, CA 92008, USA. (Email
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

4.TA Moore , RW Buchanan , PF Buckley , etal. The Texas Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007; 68(11): 17511762.

6.RW Buchanan , J Kreyenbuhl , DL Kelly , etal. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010; 36(1): 7193.

7.LB Dixon , F Dickerson , AS Bellack , etal. The 2009 PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010; 36(1): 4870.

8.J Kreyenbuhl , RW Buchanan , FB Dickerson , etal. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010; 36(1): 94103.

9.SM Stahl . How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. Acta Psychiatr Scand. 2010; 122: 440441.

10.SM Stahl . Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand. 2012; 125: 349351.

11.SM Stahl . The tyranny of the majority and the interchangeability of drugs. Acta Psychiatr Scand. 2013; 127: 45.

12.SM Stahl , DA Morrissette . Should high dose or very long term antipsychotic monotherapy be considered before antipsychotic polypharmacy? In: Ritsner MS, ed. Polypharmacy in Psychiatry Practice, Volume I: Use of Polypharmacy in the “Real World”. Dordrecht, The Netherlands: Springer Science; 2013.

13.MS Ritsner , ed. Polypharmacy in Psychiatry Practice, Volume I: Multiple Medication Use Strategies. Dordrecht, The Netherlands: Springer Science; 2013.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *